In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma

T. G. Murray, N. Cicciarelli, B. Keller, E. Hernández, B. Smith, Arnold Markoe, J. Windle, B. Ksander, J. O'Brien

Research output: Contribution to journalArticle

Abstract

Purpose: We evaluated the in vivo efficacy of external beam radiation therapy (EBRT) utilizing a clinical fractionation scheme and correlated this with previous experimental data in the murine hereditary transgenic retinoblastoma model. Methods: Ten 5 week-old SV40 Tag positive mice were entered into a control group receiving no treatment, and 60 SV40 Tag mice (6 mice/treatment point) were treated with EBRT utilizing one of two fractionation schemes at total doses of either 10, 15, 20, 30, 40, 45 or 50 Gray (Gy) of 500 centigray (cGy) twice daily treatment or 36, 56, or 76 Gy of 200 cGy once daily treatment. Animals were sacrificed at 10 weeks post-treatment and the eyes were obtained for serial section, histopathologic examination. Results: 100 % (10/10) of control eyes contained multiple, large retinal tumor foci. Dose dependent, fractionation dependent tumor control curves were generated. The 50% control point for elimination of ocular tumors occurred at 28 Gy for the 500 cGy bid treated eyes and at 51 Gy for the 200 cGy qd treated eyes. Statistical comparison generated 95% confidence intervals and a p-value of 0.001 between the two dose response curves. Conclusion: Dose fractionation significantly affects tumor control within this murine transgenic retinoblastoma model and clinically relevant dose fractionations (i.e. 200 cGy) are associated with tumor control.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996

Fingerprint

Dose Fractionation
Retinoblastoma
Radiotherapy
Radiation
Neoplasms
Retinal Neoplasms
Therapeutics
Confidence Intervals
Control Groups

ASJC Scopus subject areas

  • Ophthalmology

Cite this

In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma. / Murray, T. G.; Cicciarelli, N.; Keller, B.; Hernández, E.; Smith, B.; Markoe, Arnold; Windle, J.; Ksander, B.; O'Brien, J.

In: Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 15.02.1996.

Research output: Contribution to journalArticle

Murray, T. G. ; Cicciarelli, N. ; Keller, B. ; Hernández, E. ; Smith, B. ; Markoe, Arnold ; Windle, J. ; Ksander, B. ; O'Brien, J. / In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma. In: Investigative Ophthalmology and Visual Science. 1996 ; Vol. 37, No. 3.
@article{5e39cd1e2b51403ebd845899f747d428,
title = "In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma",
abstract = "Purpose: We evaluated the in vivo efficacy of external beam radiation therapy (EBRT) utilizing a clinical fractionation scheme and correlated this with previous experimental data in the murine hereditary transgenic retinoblastoma model. Methods: Ten 5 week-old SV40 Tag positive mice were entered into a control group receiving no treatment, and 60 SV40 Tag mice (6 mice/treatment point) were treated with EBRT utilizing one of two fractionation schemes at total doses of either 10, 15, 20, 30, 40, 45 or 50 Gray (Gy) of 500 centigray (cGy) twice daily treatment or 36, 56, or 76 Gy of 200 cGy once daily treatment. Animals were sacrificed at 10 weeks post-treatment and the eyes were obtained for serial section, histopathologic examination. Results: 100 {\%} (10/10) of control eyes contained multiple, large retinal tumor foci. Dose dependent, fractionation dependent tumor control curves were generated. The 50{\%} control point for elimination of ocular tumors occurred at 28 Gy for the 500 cGy bid treated eyes and at 51 Gy for the 200 cGy qd treated eyes. Statistical comparison generated 95{\%} confidence intervals and a p-value of 0.001 between the two dose response curves. Conclusion: Dose fractionation significantly affects tumor control within this murine transgenic retinoblastoma model and clinically relevant dose fractionations (i.e. 200 cGy) are associated with tumor control.",
author = "Murray, {T. G.} and N. Cicciarelli and B. Keller and E. Hern{\'a}ndez and B. Smith and Arnold Markoe and J. Windle and B. Ksander and J. O'Brien",
year = "1996",
month = "2",
day = "15",
language = "English",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma

AU - Murray, T. G.

AU - Cicciarelli, N.

AU - Keller, B.

AU - Hernández, E.

AU - Smith, B.

AU - Markoe, Arnold

AU - Windle, J.

AU - Ksander, B.

AU - O'Brien, J.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose: We evaluated the in vivo efficacy of external beam radiation therapy (EBRT) utilizing a clinical fractionation scheme and correlated this with previous experimental data in the murine hereditary transgenic retinoblastoma model. Methods: Ten 5 week-old SV40 Tag positive mice were entered into a control group receiving no treatment, and 60 SV40 Tag mice (6 mice/treatment point) were treated with EBRT utilizing one of two fractionation schemes at total doses of either 10, 15, 20, 30, 40, 45 or 50 Gray (Gy) of 500 centigray (cGy) twice daily treatment or 36, 56, or 76 Gy of 200 cGy once daily treatment. Animals were sacrificed at 10 weeks post-treatment and the eyes were obtained for serial section, histopathologic examination. Results: 100 % (10/10) of control eyes contained multiple, large retinal tumor foci. Dose dependent, fractionation dependent tumor control curves were generated. The 50% control point for elimination of ocular tumors occurred at 28 Gy for the 500 cGy bid treated eyes and at 51 Gy for the 200 cGy qd treated eyes. Statistical comparison generated 95% confidence intervals and a p-value of 0.001 between the two dose response curves. Conclusion: Dose fractionation significantly affects tumor control within this murine transgenic retinoblastoma model and clinically relevant dose fractionations (i.e. 200 cGy) are associated with tumor control.

AB - Purpose: We evaluated the in vivo efficacy of external beam radiation therapy (EBRT) utilizing a clinical fractionation scheme and correlated this with previous experimental data in the murine hereditary transgenic retinoblastoma model. Methods: Ten 5 week-old SV40 Tag positive mice were entered into a control group receiving no treatment, and 60 SV40 Tag mice (6 mice/treatment point) were treated with EBRT utilizing one of two fractionation schemes at total doses of either 10, 15, 20, 30, 40, 45 or 50 Gray (Gy) of 500 centigray (cGy) twice daily treatment or 36, 56, or 76 Gy of 200 cGy once daily treatment. Animals were sacrificed at 10 weeks post-treatment and the eyes were obtained for serial section, histopathologic examination. Results: 100 % (10/10) of control eyes contained multiple, large retinal tumor foci. Dose dependent, fractionation dependent tumor control curves were generated. The 50% control point for elimination of ocular tumors occurred at 28 Gy for the 500 cGy bid treated eyes and at 51 Gy for the 200 cGy qd treated eyes. Statistical comparison generated 95% confidence intervals and a p-value of 0.001 between the two dose response curves. Conclusion: Dose fractionation significantly affects tumor control within this murine transgenic retinoblastoma model and clinically relevant dose fractionations (i.e. 200 cGy) are associated with tumor control.

UR - http://www.scopus.com/inward/record.url?scp=33750155367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750155367&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750155367

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -